Genomic Testing Product of Urothelial Tumor by Genetron Health is Launched

Release time:2018-06-19

The first genomic testing product of urothelial tumor is launched in China. This new product, based on liquid biopsy technique, can assist in identifying benign or malignant urothelial tumors (bladder, renal pelvic or ureteral tumors) by detecting specific molecular changes in urine. It offers the public a new, convenient and efficient, secure and non-invasive, as well as precise and sensitive diagnosis scheme which can achieve early detection and dynamic monitoring


Current status of diagnosis of urinary system tumors


Urothelial tumors represented by bladder cancer always rank the first in the incidence of urinary system tumors. And the cure rate can be significantly improved provided that these tumors can be detected early and intervened effectively. However, conventional detection methods available in clinical applications are unsatisfactory. Take cystoscope for example, it not only makes patients (especially the male ones) extremely painful but also causes them to have psychological burden easily. Take urine exfoliation cytology detection method for another example, both sensitivity and negative prediction rate are low.Therefore, it is imperative for a new detection technique to solve difficulties in clinical diagnosis.


Genomic Testing Product of Urothelial Tumor by Genetron Health is Launched


New liquid biopsy product based on urine detection


—Urothelial tumor genomic testing


The vast majority of urothelial tumors grows and soaks in urine for a long time, and obviously, their apoptotic and necrotic cell and gene fragments are easy to come off into urine. As a result, the urine sample becomes the best choice to detect urothelial tumors via liquid biopsy technique.


As the first genomic testing product designed for urothelial tumors, this method can early detect urothelial tumors (renal pelvic, ureteral or bladder tumors) by detecting specific molecular changes in urine, and the detection process accompanies no pain or invasion. In addition, it has obvious advantages as follows.


Product Advantages


Early detection and accurate identification


The previous detection methods have a low sensitivity and easily fail to detect tumors. It often occurs that the tumor has been in middle and advanced stage when a positive result was found, thus delaying treatment. The genomic testing method of urothelial tumor can detect gene mutations driven by tumors as soon as possible, assist in identifying benign or malignant tumors, and help doctors formulate and implement effective diagnosis and treatment options.


Genomic Testing Product of Urothelial Tumor by Genetron Health is Launched


Current diagnosis and treatment of bladder cancer


Painless and non-invasive, convenient and secure


Sampling for this detection is convenient, fast and secure, and the whole process, with no injections at all, is completely painless and non-invasive. As a result, it eliminates patients’ physiological and psychological burdens caused by cystoscope, reduces their clinic time, and improves their experience of diagnosis and treatment.


Genomic Testing Product of Urothelial Tumor by Genetron Health is Launched


Detection via cystoscope causes greater physiological and psychological burdens to patients.


Precise and sensitive


By evaluating over 600 finished R&D samples (including more than 500 hematuria samples and 100 normal samples), it is found that the detection sensitivity reaches up to 90%, and its negative prediction rate for hematuria patients is greater than 99%.


Dynamic monitoring


Urothelial tumor genomic testing can help to make dynamic follow-up monitoring after surgery for the urothelial tumor. Therefore, doctors can monitor patients’ regular body indexes according to clinical requirements, knowing changes at the genomic molecular level in a very convenient way to make dynamic real-time management.


Technological advantages


Urothelial tumor genomic testing adopts “one-step method”, the core patent technology of Genetron Health. The operation of this method is simple and fast, with only one-step single tube reaction and a little manual work. Besides, its detection period is short. It takes only 7 natural days from sampling to issuing the accurate report.


Genomic Testing Product of Urothelial Tumor by Genetron Health is Launched


Service process


Genomic Testing Product of Urothelial Tumor by Genetron Health is Launched


Application scenarios


Identify whether hematuria is associated with tumor risk


Identify benign and malignant urothelial tumors


Perform follow-up monitoring after surgery for urothelial tumors (bladder, ureteral or renal pelvic tumors)


COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
Genetron Health Genetron Health Management
COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
犀牛云提供云计算服务
Messages
  • *To
  • *Subject
  • *Name
  • *Tel
  • Work Unit
  • *Email
  • 详细说明:
  • Verification code:
Genetron Health Genetron Health Management